Ovarian cancer and hormone replacement therapy - Authors' reply

Lancet

Volumn 370, Issue 9591, 2007, Pages 932-933

  Beral, Valerie ^a   Bull, Diana ^a   Green, Jane ^a   Reeves, Gillian ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE; ORAL CONTRACEPTIVE AGENT;

CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; LETTER; MORTALITY; OVARY CANCER; PRIORITY JOURNAL; STATISTICAL ANALYSIS; WOMEN'S HEALTH; CHEMICALLY INDUCED DISORDER; FEMALE; NOTE; OVARY TUMOR; PATIENT SELECTION; POSTMENOPAUSE; RISK FACTOR;

FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; OVARIAN NEOPLASMS; PATIENT SELECTION; POSTMENOPAUSE; RISK FACTORS;

EID: 34548532223     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61437-8     Document Type: Letter

References (4)

1. Million Women Study Collaborators. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369 (2007) 1703-1710
2. Mills P., Riordan D., Gress R., and Goldsmith D. Cancer Detect Prevent 29 (2005) 124-132
3. Danforth K., Tworoger S., Hecht J., Rosner B., Colditz G., and Hankinson S. A prospective study of postmenopausal hormone use and ovarian cancer risk. Br J Cancer 96 (2007) 151-156
4. Ravdin P., Cronin K., Howlander N., et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356 (2007) 1670-1674